---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-277008"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:33:55.764936+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Q3 operating expense down 26% vs Q1 2022; positive Phase 2 data for BBP-418 and infigratinib

## Summary
- Q3 operating costs $129.5M, down 26.2% from Q1 2022; net loss $137.3M vs $155.9M prior year.
- Cash, equivalents and marketable securities $558.3M, providing runway into 2024.
- BBP-418 12-month Phase 2: αDG glycosylation +0.21 at day 90, >75% creatine kinase reduction, no SAEs.
- Low-dose infigratinib Phase 2 Cohort 5 enrolled with no SAEs; AHV update in H1 2023, Phase 3 planned.
- First patient dosed in Phase 1/2 of BBP-398 plus Amgen's Lumakras for KRAS G12C; FDA Fast Track granted.

## SEC filing metadata
- accession: 0001193125-22-277008
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/0001193125-22-277008-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/d389928d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-277008
- JSON: https://secwatch.observer/filing/0001193125-22-277008.json
- Plain text: https://secwatch.observer/filing/0001193125-22-277008.txt

## Key facts
- Earnings Releases
  BridgeBio Pharma, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: BridgeBio Pharma, Inc. (the “Company”) reported recent business updates and its financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000119312522277008/0001193125-22-277008-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.